Receptor tyrosine kinases (RTKs) are major regulators of key biological processes including cell growth, survival and differentiation, and were established early on as protooncogenes, with aberrant expression linked to tumor progression in many cancers. Therefore, RTKs have emerged as major targets for selective therapy with small molecule inhibitors.
Introduction
The TAM (Tyro3, Axl, MerTK) family of receptor tyrosine kinases (RTKs) is defined by each member possessing an extracellular combination of two immunoglobulin-like domains and two fibronectin type III repeats, a transmembrane portion, and an intracellular region with intrinsic tyrosine kinase activity. The human TAM genes share similar genomic structures, and their resulting proteins share significant structural similarities, with greatest homology in the tyrosine kinase domain. The apparent molecular weights range from 100-140 kDa for Axl and Tyro3 and 165-205 kDa for MerTK due to post-translational modifications, including glycosylation, phosphorylation and ubiquitination. The established natural ligands for the TAMs are two homologous vitamin K-dependent proteins, Gas6 (all three TAMs) and Protein S (Tyro3 and MerTK) (1) .
TAM functions
All three TAMs have transforming potential; however, Axl overexpression has most frequently been detected in multiple cancers and its role in supporting tumorigenesis is well recognized. Axl supports tumour growth and dissemination through positive effects on cell survival, proliferation, migration, and invasion. Alongside these, Axl signaling is also involved in other processes ranging from the differentiation of cells in the erythroid lineage, protecting blood vessels from injury, clearance of apoptotic cells, angiogenesis, hematopoiesis, platelet aggregation and regulation of pro-inflammatory cytokine production (2, 3) . MerTK is most distinctly recognized for its role in negative regulation of the immune system through to ability to mediate phagocytosis of apoptotic cells (4) . Tyro3 has a more restricted tissue expression profile, and has been implicated in various roles including myelination in the brain (5).
The TAMs as mediators of chemoresistance
Although the TAMs are not strong oncogenes, it is increasingly clear that their overexpression contributes to acquiring resistance to both conventional as well as targeted chemotherapeutics in both solid and blood cancers. Early observations included increased Axl overexpression with resistance to the small molecule inhibitor imatinib (targets BCRAbl, c-Kit and PDGFR) in chronic myelogenous leukemia (CML) (6) and to the chemotherapy drugs doxorubicin, VP16 and cisplatin in acute myeloid leukemia (7) .
Increased resistance to imatinib due to Axl and MerTK overexpression has also been reported in gastrointestinal stromal tumors (8) and non-small lung carcinoma (9) .
MerTK overexpression has been detected in high grade glioblastomas and its knockdown to result in increased sensitivity to etoposide whilst, conversely, control cells showed elevated MerTK activation upon DNA damage with increase resistance to etoposide (10) . Inhibition of Axl and MerTK also lead to increased chemosensitivity to temozolomide, carboplatin and vincristine in astrocytoma (11) , and to cisplatin and vincristine in neuroblastoma (12) . Axl was also shown to promote resistance to ALK inhibitors in neuroblastoma through induction of epithelial-mesenchymal transition (EMT) (13) . MerTK inhibition by a monoclonal antibody was able to increase sensitivity to carboplatin in nonsmall cell lung cancer (NSCLC) due to receptor internalization and subsequent degradation which led to STAT6, Akt and ERK1/2 signaling inhibition (14) . MerTK was also shown in NSCLC to be essential for increased resistance to erlotinib through the regulation of MAPK and FAK signaling pathways (15) .
Knockdown of Axl by short hairpin (sh)RNA has revealed Axl to promote the survival of cutaneous squamous carcinoma cells through Akt activation and inhibition of the pro-apoptotic Bcl-2 family proteins (16) . Recently in melanoma, Tyro3 was identified to regulate expression of Microphthalmia-associated transcription factor (MITF), a master regulator of melanocyte development, and to promote tumorigenesis in spite of B-Rafinduced senescence (17) . Tyro3 was also shown to promote cell proliferation and chemoresistance in breast cancer (18) . In addition, downregulation of both Axl and Tyro3 was able to reverse taxol resistance in ovarian cancer (19) .
Increased Axl expression has also been associated with acquired resistance to selective EGFR small molecule inhibition. In lung cancers, this includes resistance to erlotinib through the induction of an EMT-like state (20) , as well as to gefitinib (21) . In triple-negative breast cancer cells, expression of Axl was identified as a predictor for lack of response to lapatinib and erlotinib (22) . Targeting EGFR antibodies such as cetuximab has also lead to resistance in NSCLC and head and neck carcinomas through Axl overexpression, via MAPK signaling (23) . Such an association between EGFR and Axl molecular pathways also manifests itself through hetero-interaction between EGFR and Axl molecules, which can diversify downstream signaling pathways beyond those triggered by EGFR alone (24) .
The prominent expression and functions of TAM receptors across the immune system also suggests a potential role in mediating resistance to immune checkpoint inhibitors in cancer therapy. TAM receptors are notably expressed in many myeloid immune cells including macrophages and dendritic cells, and they may cooperate to create an immunosuppressive tumor microenvironment permissive to tumorigenesis (25) . MerTK is implicated in the suppression of the M1 macrophage pro-inflammatory cytokine response, and Axl is required for the termination of Toll-like receptor dependent inflammatory response in dendritic cells (25) . Also, the TAMs have been shown to negatively regulate NK cell functional maturation and normal expression of inhibitory and activating NK cell receptors (26) . Furthermore, TAM receptors promote cancer metastases in vivo through suppression of NK cell activity, whilst treatment of wild-type NK cells with a TAM-selective small molecule inhibitor enhanced anti-metastatic NK cell activity (27) . Collectively, these data Other influences that can contribute further to TAM-mediated tumor chemoresistance could include increased expression TAM ligands, although this is not clear. Gas6 expression has been identified as a marker for poor overall survival in ovarian cancer (30) . Also, galectin-3, a sugar-binding protein that has been implicated in cancer cell behaviors (31), was indicated to be a novel ligand for MerTK (4) . Axl expression has also been correlated with markers of DNA repair in different solid cancers; Axl inhibition induced reversal of EMT and decreased expression of DNA repair genes, rendering cancer cells sensitive to PARP inhibition in a synergistic manner (32) .
TAM inhibition to treat tumour drug resistance
In addition to their roles in primary tumorigenesis, the prevalence of TAM receptors in patients displaying acquired drug-resistant tumors renders the TAMs a viable target for therapies against such evolved tumours. Importantly, TAM signaling inhibition sensitizes cells to chemotherapy, indicating that its effects are multifaceted, and the aim of "shutting down" multiple key biological processes in cancer cells can be achieved through a single target. A plethora of new, more specific and higher affinity targeting agents are currently under development ( Table 1) that may prove to be effective for preventing, delaying or combating tumour drug resistance. A recent example is from a study that showed Axl to be upregulated in CML patients that had developed resistance to BCR-Abl small molecule inhibition, including through a T315I mutation in BCR-Abl. The selective Axl small molecule inhibitor BGB324 inhibited the resistant CML cells independent of BCR-Abl mutational status (33) . This example indicates an efficacious employment of Axl inhibition at the earliest signs of resistance development to first line or targeted therapies.
Potential concerns about TAM inhibition
The MerTK double knockout mice displayed enhanced colitis resulting from insufficient neutrophil clearance (25) , and an increased production of pro-inflammatory cytokines favoring a tumor-promoting environment with enhanced colonic polyps formation (38) .
Results from current clinical trials with multikinase inhibitors including the TAMs (Table 1) 
